Clinical trial
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
NCT00276744 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Terminated
Key facts
| NCT number | NCT00276744 |
|---|---|
| Title | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer |
| Official title | A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery |
| Enrollment | 249 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Jan 13, 2006 |
| Last update posted | Oct 24, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: